A Retrospective Review of Antiphospholipid Syndrome from a South Asian Country

Overview

Journal Arch Rheumatol

Specialty Rheumatology

Date 2022 Aug 11

PMID 35949874

Authors

Muhammad Zain Mushtaq

Syed Ahsan Ali

Zaibunnisa Sattar

Saad Bin Zafar Mahmood

Tazein Amber

Mehmood Riaz

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aims to investigate clinical presentations, antiphospholipid antibody patterns and their levels, therapeutic regimens, and outcomes in patients with antiphospholipid syndrome (APS) admitted to a tertiary care hospital of a South Asian country.

Patients And Methods: Between January 2009 and December 2019, a total of 216 patients with APS (8 males, 208 females; median age: 35.7±6.9 years; range, 20 to 76 years) who either fulfilled the modified Sydney criteria or those who satisfied only clinical criteria along with positive antiphospholipid antibody on at least one occasion (probable APS) were retrospectively analyzed.

Results: The majority of the patients (n=183, 84.7%) had obstetric complications, followed by venous thrombosis in 23 (10.8%) patients. Recurrent early abortions in 126 (58.6%) and deep venous thrombosis in 16 (7.4%) patients were the most prevalent obstetrical and venous events, respectively, whereas limb gangrene in seven (3.3%) and ischemic stroke in seven (3.3%) were the most common arterial events. A total of 190 (88%) patients had primary APS, while 26 (12%) had secondary APS. Systemic lupus erythematosus was the frequent association with secondary APS found in 19 (73%) patients. Immunoglobulin M (IgM) anticardiolipin antibody was present in 173 (65.0%) patients, being the most commonly reported antibody. Probable catastrophic APS was found in four (1.9%) patients. Majority of the patients (n=190, 87.9%) were treated with a combination of acetylsalicylic acid and low-molecular-weight heparin. Single mortality was observed in our study population due to complications related to catastrophic APS.

Conclusion: Antiphospholipid syndrome has a wide range of thrombotic and obstetrical manifestations with important variations in different regions of the world. There is a significant morbidity and mortality related to APS, despite treatment with anticoagulation and; therefore, describing prognostic markers and optimal therapeutic interventions is pivotal to prevent complications.

References

Cervera R, Serrano R, Pons-Estel G, Ceberio-Hualde L, Shoenfeld Y, de Ramon E . Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2014; 74(6):1011-8. DOI: 10.1136/annrheumdis-2013-204838. View

White C, Thomason A, Boyd K . Role of Novel Oral Anticoagulants in the Treatment of Antiphospholipid Syndrome. Hosp Pharm. 2016; 51(9):759-767. PMC: 5080995. DOI: 10.1310/hpj5109-759. View

Page J, Christiansen-Lindquist L, Thorsten V, Parker C, Reddy U, Dudley D . Diagnostic Tests for Evaluation of Stillbirth: Results From the Stillbirth Collaborative Research Network. Obstet Gynecol. 2017; 129(4):699-706. DOI: 10.1097/AOG.0000000000001937. View

Galli M, Luciani D, Bertolini G, Barbui T . Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2002; 101(5):1827-32. DOI: 10.1182/blood-2002-02-0441. View

Pengo V, Tripodi A, Reber G, Rand J, Ortel T, Galli M . Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009; 7(10):1737-40. DOI: 10.1111/j.1538-7836.2009.03555.x. View

Cervera R, Boffa M, Khamashta M, Hughes G . The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus. 2009; 18(10):889-93. DOI: 10.1177/0961203309106832. View

Cervera R, Piette J, Font J, Khamashta M, Shoenfeld Y, Camps M . Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002; 46(4):1019-27. DOI: 10.1002/art.10187. View

Arslan E, Branch D . Antiphospholipid syndrome: Diagnosis and management in the obstetric patient. Best Pract Res Clin Obstet Gynaecol. 2019; 64:31-40. DOI: 10.1016/j.bpobgyn.2019.10.001. View

Espinosa G, Cervera R . Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol. 2015; 11(10):586-96. DOI: 10.1038/nrrheum.2015.88. View

10.

Cohen H, Hunt B, Efthymiou M, Arachchillage D, Mackie I, Clawson S . Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016; 3(9):e426-36. PMC: 5010562. DOI: 10.1016/S2352-3026(16)30079-5. View

11.

Graf J . Central Nervous System Manifestations of Antiphospholipid Syndrome. Rheum Dis Clin North Am. 2017; 43(4):547-560. DOI: 10.1016/j.rdc.2017.06.004. View

12.

Carmi O, Berla M, Shoenfeld Y, Levy Y . Diagnosis and management of catastrophic antiphospholipid syndrome. Expert Rev Hematol. 2017; 10(4):365-374. DOI: 10.1080/17474086.2017.1300522. View

13.

De Carolis S, Rizzo F, Tabacco S . Hydroxychloroquine as additional treatment in pregnant patients with refractory APS. Am J Obstet Gynecol. 2017; 217(6):711-712. DOI: 10.1016/j.ajog.2017.08.113. View

14.

Singh N, Behera D, Agrawal A, Singh M, Kumar V, Godhra M . Hospital based prospective longitudinal clinical and immunologic study of 179 patients of primary anti-phospholipid syndrome. Int J Rheum Dis. 2013; 16(5):547-55. DOI: 10.1111/1756-185X.12150. View

15.

Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x. View

16.

Jatuworapruk K, Bhoopat L, Hanvivadhanakul P . Clinical and immunological characteristics of antiphospholipid syndrome in an Asian population: a retrospective study. Asian Pac J Allergy Immunol. 2018; 37(3):171-178. DOI: 10.12932/AP-241217-0223. View

17.

Ruiz-Irastorza G, Crowther M, Branch W, Khamashta M . Antiphospholipid syndrome. Lancet. 2010; 376(9751):1498-509. DOI: 10.1016/S0140-6736(10)60709-X. View

18.

Taraborelli M, Reggia R, DallAra F, Fredi M, Andreoli L, Gerosa M . Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. J Rheumatol. 2017; 44(8):1165-1172. DOI: 10.3899/jrheum.161364. View

19.

Cervera R . Antiphospholipid syndrome. Thromb Res. 2017; 151 Suppl 1:S43-S47. DOI: 10.1016/S0049-3848(17)30066-X. View

20.

Bick R, BAKER W . Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost. 1999; 25(3):333-50. DOI: 10.1055/s-2007-994935. View